Boston Scientific Corporation (BSX)

US — Healthcare Sector
Peers: SYK  MDT  DHR  ISRG  PFE  GILD  AMGN  SNY  MCK  ABT 

Automate Your Wheel Strategy on BSX

With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BSX
  • Rev/Share 12.5086
  • Book/Share 15.3216
  • PB 6.545
  • Debt/Equity 0.5365
  • CurrentRatio 1.3721
  • ROIC 0.0701

 

  • MktCap 147049032158.0
  • FreeCF/Share 2.2394
  • PFCF 44.4123
  • PE 58.6436
  • Debt/Assets 0.2894
  • DivYield 0
  • ROE 0.1149

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade BSX Erste Group Buy Hold -- -- Oct. 3, 2025
Upgrade BSX Oppenheimer Perform Outperform -- $125 Sept. 8, 2025
Initiation BSX Leerink Partners -- Outperform -- $118 June 16, 2025
Upgrade BSX Needham Hold Buy -- $113 April 16, 2025
Upgrade BSX Deutsche Bank Hold Buy -- $108 Jan. 10, 2025
Downgrade BSX Needham Buy Hold -- -- Oct. 18, 2024

News

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
BSX
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Boston Scientific (BSX) and Amarin (AMRN) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Unlocking Q3 Potential of Boston Scientific (BSX): Exploring Wall Street Estimates for Key Metrics
BSX
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Read More
image for news Unlocking Q3 Potential of Boston Scientific (BSX): Exploring Wall Street Estimates for Key Metrics
Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
BSX
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.

Read More
image for news Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
BSX
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
PAHC or BSX: Which Is the Better Value Stock Right Now?
BSX, PAHC
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?

Read More
image for news PAHC or BSX: Which Is the Better Value Stock Right Now?
Medical technology stock picks for a ‘cautious' Q3: analysts
BSX
Published: October 07, 2025 by: Proactive Investors
Sentiment: Neutral

Citi analysts stressed being ‘cautious' on US medical technology stocks entering the third quarter, as the sector tends to underperform in September and October before recovering in November. In a note to clients on Tuesday, the analysts wrote that the sector was hit particularly hard this year as investors rotated out of healthcare and into technology.

Read More
image for news Medical technology stock picks for a ‘cautious' Q3: analysts
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
BSX
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Down 10.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Boston Scientific (BSX)
BSX
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Boston Scientific (BSX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Read More
image for news Down 10.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Boston Scientific (BSX)
Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
ABT, BSX
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive

UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.

Read More
image for news Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
PAHC vs. BSX: Which Stock Is the Better Value Option?
BSX, PAHC
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

Read More
image for news PAHC vs. BSX: Which Stock Is the Better Value Option?
Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?
BSX
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral

Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.

Read More
image for news Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
BSX
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
BSX
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Read More
image for news Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
BSX
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Neutral

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read More
image for news Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
BSX
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Boston Scientific (BSX) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
8 Growth Stocks to Buy That Aren't Technology. What Makes Them Worth It.
BSX, COF, UBER
Published: August 25, 2025 by: Barrons
Sentiment: Positive

As tech stocks float at historic highs, it's a good time to look elsewhere for growth. A Citi screen turned up eight names that are mostly outside the tech sector.

Read More
image for news 8 Growth Stocks to Buy That Aren't Technology. What Makes Them Worth It.
HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
BSX, HOLX
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Two MedTech giants, one clear winner. Boston Scientific's momentum outpaces Hologic's cautious rise.

Read More
image for news HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
Should Boston Scientific Stock Be in Your Portfolio Right Now?
BSX
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive

BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.

Read More
image for news Should Boston Scientific Stock Be in Your Portfolio Right Now?
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
BSX, GEHC, JNJ, TEM
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive

AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.

Read More
image for news 4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
PAHC vs. BSX: Which Stock Is the Better Value Option?
BSX, PAHC
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?

Read More
image for news PAHC vs. BSX: Which Stock Is the Better Value Option?
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
BSX
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Neutral

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
BSX
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
3 Reasons Growth Investors Will Love Boston Scientific (BSX)
BSX
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Read More
image for news 3 Reasons Growth Investors Will Love Boston Scientific (BSX)
Investors Heavily Search Boston Scientific Corporation (BSX): Here is What You Need to Know
BSX
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Investors Heavily Search Boston Scientific Corporation (BSX): Here is What You Need to Know
GEHC vs. BSX: Which Stock Is the Better Value Option?
BSX, GEHC
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?

Read More
image for news GEHC vs. BSX: Which Stock Is the Better Value Option?
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
BSX
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read More
image for news Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
BSX
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive

BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.

Read More
image for news Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
BSX
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Neutral

Boston Scientific Corporation (NYSE:BSX ) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.

Read More
image for news Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BSX
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS
BSX
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Read More
image for news Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS

About Boston Scientific Corporation (BSX)

  • IPO Date 1992-05-19
  • Website https://www.bostonscientific.com
  • Industry Medical - Devices
  • CEO Michael F. Mahoney
  • Employees 53000

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.